Overview

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2030-02-01

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

pertuzumab